| Patent Number |
Title Of Patent |
Date Issued |
| 7456251 |
HIV fusion inhibitor peptides with improved biological properties |
November 25, 2008 |
| Provided is an HIV fusion inhibitor peptide having an amino acid sequence of any one of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, or SEQ ID NO:15; and provided is a pharmaceutical composition comprising a HIV fusion inhibitor peptide and one or mo |
| 7297784 |
DNA encoding T-1249 and other viral fusion inhibitor peptides useful for treating aids |
November 20, 2007 |
| The present invention relates to enhancer peptide sequences originally derived from various retroviral envelope (gp41) protein sequences that enhance the pharmacokinetic properties of any core polypeptide to which they are linked. The invention is based on the discovery that hybrid p |
| 7045552 |
Pharmaceutical composition for improved administration of HIV gp41-derived peptides, and its use |
May 16, 2006 |
| Provided is a pharmaceutical composition comprising a solution comprised of synthetic peptide in a final concentration of not less than 70 mg/ml in admixture with a polyol; wherein the synthetic peptide is an HIV fusion inhibitor, and wherein the polyol is in a final concentration of |
| 6951717 |
Methods and compositions for inhibition of membrane fusion-associated events, including HIV tran |
October 4, 2005 |
| Parainfluenza virus types 1 to 4 (PIV1 to PIV4) are important human pathogens that cause upper and lower respiratory tract infections, particularly in infants and children. The claimed invention is directed toward novel methods for the inhibition of parainfluenza virus transmission t |
| 6861059 |
Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultane |
March 1, 2005 |
| Novel antiviral combinations for the treatment or prevention of viral infections, in particular, HIV, are disclosed. This new antiviral therapy employs either DP-178 or DP-107, viral fusion inhibitors, in combination with at least one other antiviral therapeutic agent. The combinations o |
| 6750008 |
Methods and compositions for inhibition of membrane fusion-associated events, including HIV tran |
June 15, 2004 |
| The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1.sub.LAI gp41 protein, and fragments, analogs and homologs of DP178. The invent |
| 6656906 |
Hybrid polypeptides with enhanced pharmacokinetic properties |
December 2, 2003 |
| The present invention relates to enhancer peptide sequences originally derived from various retroviral envelope (gp41) protein sequences that enhance the pharmacokinetic properties of any core polypeptide to which they are linked. The invention is based on the discovery that hybrid p |
| 6623741 |
Methods and compositions for inhibition of membrane fusion-associated events including RSV trans |
September 23, 2003 |
| The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention are derived from regions of viral fusion proteins referred to as HR1 and HR2. In particular, the invention relates to peptides referred to herein as DP107 and DP178 |
| 6562787 |
Hybrid polypeptides with enhanced pharmacokinetic properties |
May 13, 2003 |
| The present invention relates to enhancer peptide sequences originally derived from various retroviral envelope (gp41) protein sequences that enhance the pharmacokinetic properties of any core polypeptide to which they are linked. The invention is based on the discovery that hybrid p |
| 6541020 |
Methods and compositions for administration of therapeutic reagents |
April 1, 2003 |
| Methods and compositions are taught that may be used to administer specific bioactive polypeptides, known as T20 and T1249 to a patient, e.g., as a method of treating a disease or disease state. In particular, the invention teaches carrier hydrogel composition that contain (a) a polymer |
| 6518013 |
Methods for the inhibition of epstein-barr virus transmission employing anti-viral peptides capa |
February 11, 2003 |
| Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1(HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived f |
| 6479055 |
Methods for inhibition of membrane fusion-associated events, including respiratory syncytial vir |
November 12, 2002 |
| The present invention relates to peptides which exhibit potent anti-viral activity. In particular, the invention relates to methods of using such peptides as inhibitory of respiratory syncytial virus ("RSV") transmission to uninfected cells. The peptides used in the methods of the invent |
| 6475491 |
Treatment of HIV and other viral infections using combinatorial therapy |
November 5, 2002 |
| Novel antiviral combinations for the treatment or prevention of viral infections, in particular, HIV, are disclosed. This new antiviral therapy employs either DP-178 or DP-107, viral fusion inhibitors, in combination with at least one other antiviral therapeutic agent. The combinations o |
| 6469136 |
Methods and composition for peptide synthesis |
October 22, 2002 |
| The present invention relates, first, to methods for the synthesis of peptides referred to as T-1249 and T-1249-like peptides. Such methods utilize solid and liquid phase synthesis procedures to synthesize and combine groups of specific peptide fragments to yield the peptide of inter |
| 6440656 |
Methods for the inhibition of respiratory syncytial virus transmission |
August 27, 2002 |
| Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1 (HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived |
| 6348568 |
Hybrid polypeptides with enhanced pharmacokinetic properties |
February 19, 2002 |
| The present invention relates to enhancer peptide sequences originally derived from various retroviral envelope (gp41) protein sequences that enhance the pharmacokinetic properties of any core polypeptide to which they are linked. The invention is based on the discovery that hybrid p |
| 6281331 |
Methods and compositions for peptide synthesis |
August 28, 2001 |
| The present invention relates, first, to methods for the synthesis of peptides, in particular T-20 (also referred to as "DP-178"; SEQ ID NO:1) and T-20-like peptides. Such methods utilize solid and liquid phase synthesis procedures to synthesize and combine groups of specific peptide |
| 6258782 |
Hybrid polypeptides with enhanced pharmacokinetic properties |
July 10, 2001 |
| The present invention relates to enhancer peptide sequences originally derived from various retroviral envelope (gp41) protein sequences that enhance the pharmacokinetic properties of any core polypeptide to which they are linked. The invention is based on the discovery that hybrid p |
| 6228983 |
Human respiratory syncytial virus peptides with antifusogenic and antiviral activities |
May 8, 2001 |
| The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recog |
| 6093794 |
Isolated peptides derived from the Epstein-Barr virus containing fusion inhibitory domains |
July 25, 2000 |
| The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1.sub.LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention |
| 6068973 |
Methods for inhibition of membrane fusion-associated events, including influenza virus |
May 30, 2000 |
| The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1.sub.LAI gp41 protein, and fragments, analogs and homologs of DP178. The invent |
| 6060065 |
Compositions for inhibition of membrane fusion-associated events, including influenza virus tran |
May 9, 2000 |
| The present invention relates to viral peptides referred to as "DP107- and DP178-like" peptides. Specifically, the invention relates to isolated influenza A DP107- and DP178-like peptides which are identified by sequence search motif algorithms. The peptides of the invention exhibit |
| 6054265 |
Screening assays for compounds that inhibit membrane fusion-associated events |
April 25, 2000 |
| The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1.sub.LAI gp41 protein, and fragments, analogs and homologs of DP178. The invent |
| 6017536 |
Simian immunodeficiency virus peptides with antifusogenic and antiviral activities |
January 25, 2000 |
| The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a simian immunodeficiency virus (SIV) protein. These regions were identified through computer algorithms capable of rec |
| 6013263 |
Measles virus peptides with antifusogenic and antiviral activities |
January 11, 2000 |
| The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1.sub.LAI gp41 protein, and fragments, analogs and homologs of DP178. The invent |
